Surge Manufacturing For Biopharma Resilience

Kayla Hannon was in the trenches at Moderna when the company faced a once-in-a-century manufacturing challenge to produce a billion doses of vaccine at the height of the COVID pandemic. On those front lines, she played an active role in the advent of a surge manufacturing strategy that she now espouses as Manager of Process Engineering at TFF Pharmaceuticals.

Zoltán Kis, Ph.D. is a lecturer at The University of Sheffield and a fast-rising leader in RNA vaccine and therapeutic production optimization. He’s currently leading the Wellcome Leap R3 RNA Readiness + Response project, aimed at building a global network of distributed, multi-product, RNA-based manufacturing capabilities for access to diverse biologics and sustainable pandemic response.

Check out Bioprocess Online Live where we took a hard look at what surge manufacturing is and how mobility, modularity, single-use, and process train redundancy enable the scale required of biopharmas to meet variable public health demands. Available on-demand thanks to the support of Cytiva.